- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
David O'Malley, MD | Authors
David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
May 16, 2022
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
May 06, 2022
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
David M. O’Malley, MD, Discusses Recent Approval of Pembrolizumab in Endometrial Cancer
April 27, 2022
David M. O’Malley, MD, spoke about the approval of pembrolizumab for patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient.
David O’Malley, MD, Discusses Findings From the OReO Trial in Ovarian Cancer at 2021 ESMO
September 23, 2021
CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.